Advertisement

Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial

Published:November 19, 2022DOI:https://doi.org/10.1016/j.brachy.2022.08.015

      Abstract

      PURPOSE

      To report acute toxicity and health-related quality of life (HRQoL) outcomes of a phase II clinical trial of magnetic resonance imaging (MRI)-guided prostate high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy.

      METHODS AND MATERIALS

      Patients with intermediate- and high-risk prostate cancer (PCa) were eligible. Treatment consisted of a single 15 Gy MRI-guided HDR-BT followed by external beam radiotherapy (37.5–46 Gy depending on their risk category). Dosimetry, toxicity and HRQoL outcomes were collected prospectively at baseline, 1 and 3 months using Common Terminology Criteria for Adverse Events Version 4.0 and the expanded PCa index composite, respectively. General linear mixed modeling was conducted to assess the changes in expanded PCa index composite domain scores over time. A minimally important difference was defined as a deterioration of HRQoL scores at 3 months compared to baseline ≥ 0.5 standard deviation. A p value ≤ 0.05 was considered statistically significant.

      RESULTS

      Sixty-one patients were included. Acute grade (G)2 urinary toxicity was observed in 18 (30%) patients while 1 (2%) patient had G3 toxicity, and none had G4 toxicity. Two patients had an acute urinary retention. G2 gastrointestinal toxicity was reported by 5 (8%) patients with no G3–4. Compared to baseline, urinary HRQoL scores significantly declined at 1 month (p < 0.001) but recovered at 3 months (p > 0.05). Bowel (p < 0.001) and sexual (p < 0.001) domain scores showed a significant decline over the 3-month follow-up period. At 3 months, 44%, 49% and 57% of patients reported a minimally important difference respectively in the urinary bowel and sexual domains.

      CONCLUSION

      MRI-guided HDR-BT boost is a safe and well tolerated treatment of intermediate- and high-risk PCa in the acute setting. A longer follow-up and a comparison to ultrasound-based HDR-BT are needed to assess the potential benefit of MRI-guided prostate HDR-BT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Al-Mamgani A.
        • van Putten W.L.J.
        • Heemsbergen W.D.
        • et al.
        Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72: 980-988
        • Dearnaley D.P.
        • Jovic G.
        • Syndikus I.
        • et al.
        Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
        Lancet Oncol. 2014; 15: 464-473
        • Viani G.A.
        • Stefano E.J.
        • Afonso S.L.
        Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.
        Int J Radiat Oncol Biol Phys. 2009; 74: 1405-1418
        • Morris W.J.
        • Tyldesley S.
        • Rodda S.
        • et al.
        Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
        • Smith G.D.
        • Pickles T.
        • Crook J.
        • et al.
        Brachytherapy improves biochemical failure–free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
        Int J Radiat Oncol Biol Phys. 2015; 91: 505-516
        • Helou J.
        • D'Alimonte L.
        • Loblaw A.
        • et al.
        High dose-rate brachytherapy boost for intermediate risk prostate cancer: long-term outcomes of two different treatment schedules and early biochemical predictors of success.
        Radiother Oncol. 2015; 115: 84-89
        • Deutsch I.
        • Zelefsky M.J.
        • Cahlon O.
        • et al.
        Comparison of PSA relapse free survival in patients treated with ultra-high dose IMRT versus combination HDR brachytherapy and IMRT.
        Int J Radiat Oncol Biol Phys. 2008; 72: S135
        • Morton G.C.
        High-dose-rate brachytherapy boost for prostate cancer: rationale and technique.
        J Contemp Brachyther. 2014; 6: 323-330
        • Spratt D.E.
        • Zumsteg Z.S.
        • Ghadjar P.
        • et al.
        Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer: ultra-high-dose IMRT vs combination therapy.
        BJU Int. 2014; 114: 360-367https://doi.org/10.1111/bju.12514
        • Morton G.C.
        • Loblaw D.A.
        • Sankreacha R.
        • et al.
        Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
        Int J Radiat Oncol Biol Phys. 2010; 77: 811-817
        • Rodda S.
        • Tyldesley S.
        • Morris W.J.
        • et al.
        ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachy-therapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 286-295
        • Schmid M.
        • Crook J.M.
        • Batchelar D.
        • et al.
        A phantom study to assess ac-curacy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants.
        Brachytherapy. 2013; 12: 56-64
        • McLaughlin P.W.
        • Evans C.
        • Feng M.
        • et al.
        Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy.
        Int J Radiat Oncol Biol Phys. 2010; 76: 369-378
        • Petrik D.
        • Araujo C.
        • Kim D.
        • et al.
        Implications of CT imaging for postplan quality assessment in prostate brachytherapy.
        Brachytherapy. 2012; 11: 435-440
        • de Rooij M.
        • Hamoen E.H.J.
        • Witjes J.A.
        • et al.
        Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis.
        Eur Urol. 2016; 70: 233-245
        • Hamoen E.H.J.
        • de Rooij M.
        • Witjes J.A.
        • et al.
        Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis.
        Eur Urol. 2015; 67: 1112-1121
        • Venkatesan A.M.
        • Stafford R.J.
        • Duran C.
        • et al.
        Prostate magnetic resonance imaging for brachytherapists: anatomy and technique.
        Brachytherapy. 2017; 16: 679-687
        • Murgic J.
        • Chung P.
        • Berlin A.
        • et al.
        Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer.
        Brachytherapy. 2016; 15: 147-155
        • Ménard C.
        • Iupati D.
        • Publicover J.
        • et al.
        MR-guided prostate biopsy for planning of focal salvage after radiation therapy.
        Radiology. 2015; 274: 181-191
        • Pulvirenti T.
        • Chung P.
        • Morton G.
        • et al.
        Salvage MRI-guided and tumor-targeted HDR prostate brachytherapy after external beam radiotherapy.
        Brachytherapy. 2014; 13: S38-S39
        • Edge S.B.
        • Compton D.
        • Fritz C.
        • et al.
        (editors)AJCC cancer staging manual. 7. Springer, New York, NY2010
        • Sanmamed N.
        • Chung P.
        • Berlin A.
        • et al.
        Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: impact on acute urinary toxicity and health-related quality of life.
        Brachytherapy. 2019; 18: 477-483
        • Lessard E.
        • Pouliot J.
        Inverse planning anatomy-based dose optimization for HDR-brachytherapy of the prostate using fast simulated annealing algorithm and dedicated objective function.
        Med Phys. 2001; 28: 773-779
        • Yamada Y.
        • Rogers L.
        • Demanes D.J.
        • et al.
        American Brachy-therapy Society consensus guidelines for high-dose-rate prostate brachytherapy.
        Brachytherapy. 2012; 11: 20-32
      1. Common Terminology Criteria for Adverse Events (CTCAE) | Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. 2018. Available at: ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.

        • Wei J.T.
        • Dunn R.L.
        • Litwin M.S.
        • et al.
        Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
        Urology. 2000; 56: 899-905
        • Dunn R.L.
        Scoring Instructions for the Expanded Prostate cancer Index Composite (EPIC)*.
        Response. 2002; 734
        • Norman G.R.
        • Sloan J.A.
        • Wyrwich K.W.
        Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.
        Med Care. 2003; 41: 582-592
        • Hoskin P.J.
        • Rojas A.M.
        • Bownes P.J.
        • et al.
        Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
        Radiother Oncol. 2012; 103: 217-222
        • Khor R.
        • Duchesne G.
        • Tai K.-.H.
        • et al.
        Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2013; 85: 679-685
        • Phan T.P.
        • Syed A.M.N.
        • Puthawala A.
        • et al.
        High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
        J Urol. 2007; 177: 123-127
        • Shahid N.
        • Loblaw A.
        • Chung H.T.
        • et al.
        Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer.
        Clin Oncol (R Coll Radiol). 2017; 29: 412-420
        • Vigneault E.
        • Mbodji K.
        • Magnan S.
        • et al.
        High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes.
        Radiother Oncol. 2017; 124: 49-55
        • Sathya J.R.
        • Davis I.R.
        • Julian J.A.
        • et al.
        Randomized trial comparing iridium implant plus external-beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate.
        J Clin Oncol. 2005; 23: 1192e1199
        • Pellizzon A.C.A.
        • Fogaroli R.C.
        • Silva M.L.G.
        • et al.
        High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control.
        Int J Clin Exp Med. 2011; 4: 43-52
        • Hsu I.-.C.J.
        • Cabrera A.R.
        • Weinberg V.
        • et al.
        Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.
        Brachytherapy. 2005; 4: 202-206
        • Boladeras A.
        • Santorsa L.
        • Gutierrez C.
        • et al.
        External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.
        Radiother Oncol. 2014; 112: 227-232
        • Helou J.
        • Morton G.
        • Kiss A.
        • et al.
        A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer.
        Radiother Oncol. 2022; 171: 164-172
        • Choudhury A.
        • Arthur C.
        • Malik J.
        • et al.
        Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
        Clin Oncol. 2014; 26: 661-667
        • Zaorsky N.G.
        • Doyle L.A.
        • Yamoah K.
        • et al.
        High dose rate brachytherapy boost for prostate cancer: a systematic review.
        Cancer Treat Rev. 2014; 40: 414-425